DDL-218

• Description :

  DDL-218 is an orally active and potent SirT1 inhibitor. DDL-218 enhances SirT1 in ApoE4-expressing neurons and a murine AD model. DDL-218 can be used in the study of Alzheimer's disease[1].

• UNSPSC :

  12352005

• Target :

  Sirtuin

• Related Pathways :

  Cell Cycle/DNA Damage; Epigenetics

• Field of Research :

  Neurological Disease

• Purity :

  99.49

• Smiles :

  N[C@@H](C)C(OC(C)(C)CC1=CC=NC=C1)=O

• Molecular Formula :

  C12H18N2O2

• Molecular Weight :

  222.28

• References & Citations :

  [1]Campagna J, et al. Discovery of an ApoE4-targeted small-molecule SirT1 enhancer for the treatment of Alzheimer's disease. Sci Rep. 2025 Apr 23;15 (1) :14028.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2767324-34-3]